
Dalbeth, N., Gosling, A. L., Gaffo, A. & Abhishek, A. Gout. Lancet (London England) 397(10287), 1843–1855 (2021).
Li, C., Hsieh, M. C. & Chang, S. J. Metabolic syndrome, diabetes, and hyperuricemia. Curr. Opin. Rheumatol. 25(2), 210–216 (2013).
Amiya, E. Link between hyperuricemia, renal dysfunction, and hypertension. J. Clin. Hypertens. (Greenwich) 23(12), 2078–2079 (2021).
Zhang, S. et al. Hyperuricemia and cardiovascular disease. Curr. Pharm. Des. 25(6), 700–709 (2019).
Ramirez-Sandoval, J. C. & Madero, M. Treatment of hyperuricemia in chronic kidney disease. Contrib. Nephrol. 192, 135–146 (2018).
Butler, F., Alghubayshi, A., Roman, Y. The epidemiology and genetics of hyperuricemia and gout across major racial groups: A literature review and population genetics secondary database analysis. J. Personal. Med. 11(3) (2021).
Levey, A. S. et al. Chronic kidney disease as a global public health problem: Approaches and initiatives—a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 72(3), 247–259 (2007).
Coresh, J. et al. Prevalence of chronic kidney disease in the United States. JAMA. 298(17), 2038–2047 (2007).
Zhang, L. et al. Prevalence of chronic kidney disease in China: A cross-sectional survey. Lancet (London, England). 379(9818), 815–822 (2012).
Sturm, G., Kollerits, B., Neyer, U., Ritz, E. & Kronenberg, F. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp. Gerontol. 43(4), 347–352 (2008).
Madero, M. et al. Uric acid and long-term outcomes in CKD. Am. J. Kidney Dis. 53(5), 796–803 (2009).
Dousdampanis, P., Trigka, K., Musso, C. G. & Fourtounas, C. Hyperuricemia and chronic kidney disease: An enigma yet to be solved. Renal Failure. 36(9), 1351–1359 (2014).
Giordano, C., Karasik, O., King-Morris, K. & Asmar, A. Uric acid as a marker of kidney disease: Review of the current literature. Dis. Mark. 2015, 382918 (2015).
Gul, A., Harford, A. & Zager, P. Mendelian randomization to establish the causality of uric acid with diabetic nephropathy in type 1 diabetics. Kidney Int. 91(5), 1005–1007 (2017).
Zoccali, C. & Mallamaci, F. Uric acid in chronic kidney disease: the quest for causality continues. Nephrol. Dialysis Transplant. 33(2), 193–195 (2018).
Li, L. et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 15, 122 (2014).
Srivastava, A., Kaze, A. D., McMullan, C. J., Isakova, T. & Waikar, S. S. Uric acid and the risks of kidney failure and death in individuals with CKD. Am. J. Kidney Dis. 71(3), 362–370 (2018).
Lee, C. L. & Tsai, S. F. Association between mortality and serum uric acid levels in non-diabetes-related chronic kidney disease: An analysis of the National Health and Nutrition Examination Survey, USA, 1999–2010. Sci. Rep. 10(1), 17585 (2020).
Tsai, C. W. et al. Uric acid predicts adverse outcomes in chronic kidney disease: a novel insight from trajectory analyses. Nephrol. Dial. Transplant. 33(2), 231–241 (2018).
Prezelin-Reydit, M. et al. Longitudinal uric acid has nonlinear association with kidney failure and mortality in chronic kidney disease. Sci. Rep. 13(1), 3952 (2023).
Siu, Y. P., Leung, K. T., Tong, M. K. & Kwan, T. H. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am. J. Kidney Dis. 47(1), 51–59 (2006).
Goicoechea, M. et al. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. Am. J. Kidney Dis. 65(4), 543–549 (2015).
Sircar, D. et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: A 6-month, double-blind, randomized, placebo-controlled trial. Am. J. Kidney Dis. 66(6), 945–950 (2015).
Goicoechea, M. et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin. J. Am. Soc. Nephrol.: CJASN. 5(8), 1388–1393 (2010).
Kim, C. S. et al. Relationship between serum uric acid and mortality among hemodialysis patients: Retrospective analysis of Korean end-stage renal disease registry data. Kidney Res. Clin. Pract. 36(4), 368–376 (2017).
Chini, L. S. N., Assis, L. I. S. & Lugon, J. R. Relationship between uric acid levels and risk of chronic kidney disease in a retrospective cohort of Brazilian workers. Braz. J. Med. Biol. Res. 50(9), e6048 (2017).
Chonchol, M. et al. Relationship of uric acid with progression of kidney disease. Am. J. Kidney Dis. 50(2), 239–247 (2007).
Sampson, A. L., Singer, R. F., Walters, G. D. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease. Cochrane Database Syst Rev. 10(10):Cd009460 (2017).
Kibria, G. M. A. & Crispen, R. Prevalence and trends of chronic kidney disease and its risk factors among US adults: An analysis of NHANES 2003–18. Prev Med Rep. 20, 101193 (2020).
Otani, N. et al. Effects of uric acid on vascular endothelial function from bedside to bench. Hypertension Res. 41(11), 923–931 (2018).
Wang, X. D. et al. Correlation between the elevated uric acid levels and circulating renin-angiotensin-aldosterone system activation in patients with atrial fibrillation. Cardiovasc. Diagn. Ther. 11(1), 50–55 (2021).
Ponticelli, C., Podestà, M. A. & Moroni, G. Hyperuricemia as a trigger of immune response in hypertension and chronic kidney disease. Kidney Int. 98(5), 1149–1159 (2020).
Badve, S. V. et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 382(26), 2504–2513 (2020).
Doria, A. et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med. 382(26), 2493–2503 (2020).
Suliman, M. E. et al. J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis. 48(5), 761–771 (2006).
Odden, M. C., Amadu, A. R., Smit, E., Lo, L. & Peralta, C. A. Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988–1994 and 1999–2002. Am. J. Kidney Dis. 64(4), 550–557 (2014).
FitzGerald, J. D. et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res. 72(6), 744–760 (2020).
CSo e. Guideline for the diagnosis and management of hyperuricemia and gout in China (2019). Chin. J. Endocrinol. Metab. 36(01), 1–13 (2020).
Wang, H., Zhang, H., Sun, L. & Guo, W. Roles of hyperuricemia in metabolic syndrome and cardiac-kidney-vascular system diseases. Am. J. Transl. Res. 10(9), 2749–2763 (2018).
Kuwabara, M. et al. Hyperuricemia is an independent competing risk factor for atrial fibrillation. Int. J. Cardiol. 231, 137–142 (2017).
Wu, X. et al. Asymptomatic hyperuricemia and incident congestive heart failure in elderly patients without comorbidities. Nutr. Metab. Cardiovasc. Dis.: NMCD. 30(4), 666–673 (2020).
Jayachandran, M. & Qu, S. Harnessing hyperuricemia to atherosclerosis and understanding its mechanistic dependence. Med. Res. Rev. 41(1), 616–629 (2021).
Li, M., Hou, W., Zhang, X., Hu, L. & Tang, Z. Hyperuricemia and risk of stroke: A systematic review and meta-analysis of prospective studies. Atherosclerosis. 232(2), 265–270 (2014).
- The Renal Warrior Project. Join Now
- Source: https://www.nature.com/articles/s41598-023-51010-6